JAN 3 1 2003 5

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	7		<u></u>			,				\mathcal{I}	1216
Substi	tute	form 144	то		<i>:</i>	Арр	lication Number	09/843,15	9	7 7	
INI	EΩI	DM AT	ION F	DISCLO	SIIDE	Filin	g Date	April 25, 2	2001	UL	IVE
				APPL		First	Named Inventor	LUO, Ying) FF	B 0 3	2003
"				as necessa		Art l	Jnit	1652			
		oo ao ma				Exar	niner Name	RAO, M.	TECH C	ENTER	1600/
Sheet	t	1	of	2		Atto	rney Docket Number	A-68292-2	/RMS/DHR;	467802	-217
					U.S. PAT	ENT	DOCUMENTS				
*Examiner	Cite No.		CUMENT N	IUMBER le (if known)	Publication MM-DD-Y		Name of Patente Applicant of Cited Do		Pages, Co Where Relevant Fi	ant Passa	iges or
me	A4	US-	6,455,290) B1	09/24/2002	2	Berthelsen et al.	-		<u></u>	
	A5	US-	6,277,613	B1	08/21/2001		De Lange et al.				
My	A6	us-	6,387,902	PB1	05/14/2002	2	Zhang et al.				
	_	US-									
		US-									
,	 —	US-			<u> </u>						
		US-									
	-	US-							,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
		US-									
		US-									
	-	US- US-									
		US-									
		US-	<u> </u>								
	11			F	ORFIGN PA	ΔTEN	IT DOCUMENTS	,			
		F	OREIGN PA	ATENT			TOOOMENTS				
*Examiner	Cite	Country		- Kind Code	Publication Da	, to		Pages, Co	lumns, Lines,	TRANSL	ATION ,
Initial	No.	Code:	(if)	known)	MM-DD-YYY		Name of Patentee or pplicant of Cited Document	Where Rele	vant Passages Figures Appear	YES	NO
my	В8	wo	01/0432	26 A1	01/18/2001	В	erthelsen et al.				
	B9	wo.	00/7722	25 A1	12/21/2000	С	hi et al.				
				·							
		 		 							
								ļ			
EXAMII	NER S	SIGNATUF	se V	m		•	Aliz	60)			
+=>/444		1 11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1					· · · · · · · · · · · · · · · · · · ·			_	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

•				PE				
Substitute f	or for	n 1449A	PTO	0.4.2002 W	Application Number	09/843,159 REA	~ P-10	,
INIEO	DA	1 A TI		JAN 3 1 2003 P	Filing Date	April 25, 2001	ノニハ	VEI
INFO	YKIV TEN	IA I IL		SCLOSURE APPLICANT	First Named Inventor	LUO, Ying FEB	032	002
				as necessary)	Art Unit	1652		, i
(use a	is many		, as necessary)	Examiner Name	RAO, M. TECH CENT	ER 16	00/29
Sheet	2		of	2	Attorney Docket Number	A-68292-2/RMS/DHR; 4	67802-	217
		ОТ	HER	DOCUMENTS - NO	N-PATENT LITERATUR	E DOCUMENTS		
*Examiner Cit	te		nclude n	ame of the author (in CAPITA	AL LETTERS), title of the article (when ial, symposium, catalog, etc.), date, pa	appropriate), title of the	TRANSI	LATION
Initials No). 			number(s), publis	sher, city and/or country where publish	ed	YES	NO
	27	Inhibite	or Mole	ecules of Poly(ADP-rib	onisotopic Test to Screen a l lose) Polymerase Activity for earch, 5:1169-1172, May 1999	r Therapeutic		
Leng C	28	RANKI	N, P.W		Studies of Inhibitors of ADP-			
			- "					
				_				
EXAMINE				Lung	DATE CONSIDERED		11	
*EXAMINI citation if	ER: not in	Initial if conform	referer nance a	nce considered, whether nd not considered. Inclu	or not citation is in conformar de copy of this form with next co	nce with MPEP 609. Draw ommunication to applicant.	line th	rough



Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no constant are restricted to respond to a collection of information unless it contains a valid OMB

Control number.

0 5 2002

Complete if Known Substitute for form 1449A/PTO 09/843,159 **Application Number** INFORMATION DISCLOSURE **Filing Date** April 25, 2001 STATEMENT BY APPLICANT First Named Inventor Luo TECH CENTER 1600/2900 Group Art Unit 1653 (use as many sheets as necessary) Unknown **Examiner Name** Attorney Docket Number A-68292-2/RMS/DHR Sheet of

	U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1		t Document Kind Code ² (if known)		Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
mine	A1	5,861,259		Roberts et al.	01/1999		
'\	A2	5,726,025		Kirschner et al.	10/1998		
le Lago	А3	6,387,902	B1	Zhang et al.	05/14/2002		
				·			
,	1						
		0.007					

		FOREIGN PATENT DOCUME			
Cite No.1	Kind Co	de ² Name of Detentes or Applicant	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	т°
B1	WO 99/15647	Daly, et al.	04/01/1999		
B2	WO 99/64608		12/16/1999~		
B3	WO 00/42040		07/2 0/2000 ~		
B4	WO 98/45437		10/15/1998		
85	WO 01/00849	0 -	01/04/2001-		
-B8	WO 00/72021		11/20/2000-		
B7	WO 00/61813		10/19/2000		
	No.¹ B1 B2 B3 B4 B5 B6	Cite No. 1 Office Number (if know) B1 WO 99/15647 B2 WO 99/64608 B3 WO 00/42040 B4 WO 98/45437 B5 WO 01/00849 B0 WO 00/72024	No.1 Office Number (if known) of Cited Document B1 WO 99/15647 Daly, et al. B2 WO 99/64608 B3 WO 00/42040 B4 WO 98/45437 B5 WO 01/00849 C C C C C C C C C C C C C C C C C C C	Cite No. 1 Office Number (if known) Name of Patentee or Applicant of Cited Document MM-DD-YYYY B1 WO 99/15647 Daly, et al. 04/01/1999 B2 WO 99/64606 Daly, et al. 04/01/1999 B3 WO 00/42040 Daly, et al. 07/20/2000 B4 WO 98/45437 Daly, et al. 04/01/1999 B5 WO 01/00849 O 01/00849 B6 WO 00/72021	Foreign Patent Document Kind Code Name of Patentee or Applicant of Cited Document MM-DD-YYYY Passages or Relevant Passages or

Examiner Signature	huy	Date Considered	4/13	103_	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

PTO/SB/8B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE ed to respond to a collection of information unless it contains a valid OMB

Under the Paperwork Reduction Act of 1995, no person are Reduction Act of 1995, no pe

Attorney Docket Number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of

	Complete if Known	RECEIVED
Application Number	09/843,159	HECEIVED
Filing Date	April 25, 2001	NOV 0 7 4000
First Named Inventor	Luo	NOV 0 7 2 002
Group Art Unit	1653	
Evaminer Name	Unknown	TECH_CENTER_T600/2900

A-68292-2/RMS/DHR

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
Leur	C1	Smith et al., "Tankyrase, a poly (ADP-ribose) polymerase at human telomeres," Science, 282(5393):1484-1487 (November 1998).				
}	C2	Mera, S., "The role of telomeres in aging and cancer," Br J Biomed Sci, 55(3):221-225 (September 1998).				
	СЗ	Lux et al., "Analysis of cDNA for human erythrocyte ankyrin indicates a repeated structure with homology to tissue-differentiation and cell-cycle control proteins," Nature, 344(6261):36-42 (March 1990).				
	C4	Bryan et al., "Telomerase and the maintenance of chromosome ends," Curr Opin Cell Biol, 11(3):318-324 (June 1999).				
	C5	Hiyama et al., "Overexpression of human telomerase RNA is an early event in oesophageal carcinogenesis," Virchows Arch, 434(6):483-487 (June 1999).				
	C6	Krejc, K., "An in situ study of variant telomeric repeats in human chromosomes," Genomics, 58(2):202-206 (June 1999).				
	C7	Holt et al., "Role of telomerase in cellular proliferation and cancer," J Cell Physiol, 180(1):10-18 (July 1999).				
	C8	Tan, Z., "Intramitotic and intraclonal variation in proliferative potential of human diploid cells: explained by telomere shortening," J Theor Biol, 198(2):259-268 (May 1999).				
	С9	Zhu et al., "Chromosomal mapping of the tankyrase gene in human and mouse", Genomics 57:320-321 (1999)				
	C10	Daly, "The Grb7 Family of Signalling Proteins," Cell. Signal 10(9):613-618 (1998)				
	C11	Janes, et al., "Structural Determinants of the Interaction between the erbB2 Receptor and the Src Homology 2 Domain of Grb7," J Biol Chem 272(13):8490-8497 (1997)				
	C12	Daly, "Take Your Partners, Please - Signal Diversification by the erbB Family of Receptor Tyrosine Kinases," Growth Factors 16:255-263 (1999)				
	C13	Bowie et al., "Deciphering the message in protein sequences: tolerance to amino acid substitutions," Science 247:1306-1310 (1990)				
	C14	Burgess et al., "Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue," J Cell Bio. 111(5 pt 1):2129-2138 (1990)				
	C15	Scott et al., "The Pendred syndrome gene encodes a chloride-iodide transport protein," Nat Genet 21(4):440-443 (1999)				
	C16	Bork, P., "Powers and Pitfalls in sequence analysis: the 70% hurdle," Genome Res 10(4):398-400 (2000)				
mm	C17	Reiger et al., Glossary of Genetics and Cytogenetics, Classical and Molecular 4th Ed., Springer-Verlay, Berlin, pp. 17-18 (1976)				

Examiner	~~/	Date	1 .		
	m	l Date		10100	
Signature	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	I Consi	idered LN	ハンコリン	
		001131	acica m	כ עוט או	
				<u> </u>	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/8B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE to respond to a collection of information unless it contains a valid OMB Under the Paperwork Reduction Act of 1995, no personal regions

control number. Complete if Known Substitute for form 1449B/PTO Application Number 09/843,159 **INFORMATION DISCLOSURE** Filing Date April 25, 2001 STATEMENT BY APPLICANT First Named Inventor

Group Art Unit 1653 (use as many sheets as necessary) **Examiner Name** Unknown Sheet Attorney Docket Number A-68292-2/RMS/DHR

Luo

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
C18	different biological activities," Mol Cell Biol 8(3):1247-1252 (1988)	
C19	Harris et al., "Polycystic kidney disease. 1: Identification and analysis of the primary defect," J Am Soc Nephrol 6(4):1125-1133 (1995)	
C20	Ahn, et al., "The structural and functional diversity of dystrophin," Nat Genet 3(4):283-291 (1993)	
C21	Cawthon et al., "cDNA sequence and genomic structure of EV12B, a gene lying within an intron of the neurofibromatosis type 1 gene," Genomics 9(3):446-460 (1991)	
C22	Database SWALL:CGA1_XENLA, accession P18606 (Nov. 1990), Cyclin A1	
C23	Database SWALL:CGB1_XENLA, accession P13350 (Jan 1990), G2/Mitotic-specific Cyclin B1	
C24	Database SWALL:CGB1_HUMAN, accession P14635 (Apr 1990), G2/Mitotic-specific Cyclin B1	
C25	Database EMBL:MMAA24592, accession AA124592 (Nov 1996), mp86g12.r1 Soares_thymus_2NbMT Mus musculus cDNA clone similar to gb:M25753 G2/Mitotic-specific Cyclin B1 (Human)	
C26	Database EMBL:HSZZ78609, accession AA373339 (Apr 1997), EST85503 HSC172 cells I Homo sapiens cDNA 5' end similar to cyclin B, mRNA sequence	
	C18 C19 C20 C21 C22 C23 C24 C25	Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. C18 Lazar, et al., "Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities," Mol Cell Biol 8(3):1247-1252 (1988) C19 Harris et al., "Polycystic kidney disease. 1: Identification and analysis of the primary defect," J Am Soc Nephrol 6(4):1125-1133 (1995) C20 Ahn, et al., "The structural and functional diversity of dystrophin," Nat Genet 3(4):283-291 (1993) C21 Cawthon et al., "cDNA sequence and genomic structure of EV12B, a gene lying within an intron of the neurofibromatosis type 1 gene," Genomics 9(3):446-460 (1991) C22 Database SWALL:CGA1_XENLA, accession P18606 (Nov. 1990), Cyclin A1 C23 Database SWALL:CGB1_HUMAN, accession P14635 (Apr 1990), G2/Mitotic-specific Cyclin B1 C24 Database EMBL:MMAA24592, accession AA124592 (Nov 1996), mp86g12.r1 Soares_thymus_2NbMT Mus musculus cDNA clone similar to gb:M25753 G2/Mitotic-specific Cyclin B1 (Human) Database EMBL:HSZZ78609, accession AA373339 (Apr 1997), EST85503 HSC172 cells I Homo sapiens

Examiner Signature	my	Date Considered	413/03

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.